Analysts have been eager to weigh in on the Healthcare sector with new ratings on Marinus (MRNS), Abiomed (ABMD) and Albireo Pharma (ALBO).
Marinus (MRNS)
Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on Marinus today and set a price target of $4.50. The company’s shares closed last Thursday at $1.94.
According to TipRanks.com, Higgins is ranked 0 out of 5 stars with an average return of -6.0% and a 30.9% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Zynerba Pharmaceuticals, and Armata Pharmaceuticals.
Currently, the analyst consensus on Marinus is a Strong Buy with an average price target of $6.50.
See today’s analyst top recommended stocks >>
Abiomed (ABMD)
In a report released today, Marie Thibault from BTIG maintained a Hold rating on Abiomed. The company’s shares closed last Thursday at $312.15, close to its 52-week high of $319.19.
According to TipRanks.com, Thibault is a 4-star analyst with an average return of 24.2% and a 61.8% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Varian Medical Systems, and Edwards Lifesciences.
Currently, the analyst consensus on Abiomed is a Moderate Buy with an average price target of $233.33.
Albireo Pharma (ALBO)
Needham analyst Alan Carr assigned a Buy rating to Albireo Pharma today and set a price target of $50.00. The company’s shares closed last Thursday at $26.70.
According to TipRanks.com, Carr is a 3-star analyst with an average return of 0.8% and a 41.2% success rate. Carr covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Phathom Pharmaceuticals, and ACADIA Pharmaceuticals.
Albireo Pharma has an analyst consensus of Strong Buy, with a price target consensus of $50.83, representing a 104.5% upside. In a report issued on July 30, Wedbush also assigned a Buy rating to the stock with a $55.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.